Loading...

LPH

DRTS

ALPHA TAU MEDICAL LTD

(DRTS)

2026 6-K

Pancreatic Cancer Data

31 Mar '26

Financial Results Update

9 Mar '26

Marketing Approval Granted

24 Feb '26

Shareholder Update

29 Jan '26

Positive Results Reported

6 Jan '26

FDA Submission Update

5 Jan '26

Conference Announcement

18 Dec '25

Trial Patient Treatment

9 Dec '25

Upcoming Symposium

4 Dec '25

FDA Approval Announcement

2 Dec '25

Quarterly Results Update

20 Nov '25

Radioactive License Granted

21 Oct '25

Clinical Trial Update

2 Sep '25

Investor Conferences Announ...

27 Aug '25

Financial Update

11 Aug '25

Annual Meeting Results

17 Jun '25

Healthcare Conference Update

28 May '25

Q1 Financial Results

19 May '25

Annual Meeting Notice

13 May '25

Board Appointment

12 May '25

Investor Conference Attendance

6 May '25

Share Purchase Agreement

28 Apr '25

FDA Trial Approval

2 Apr '25

Financial Update

12 Mar '25

Investor Conference Announc...

27 Feb '25

MDSAP Certification

24 Feb '25

FDA Approval Announcement

3 Feb '25

R&D Update Data

27 Jan '25

New Data Presentation

18 Dec '24

Board Changes Announced

17 Dec '24

Shareholder Meeting Recap

17 Dec '24

Conference Announcement

11 Dec '24

Investor Symposium Update

6 Dec '24

Q3 Financial Update

19 Nov '24

Conference Participation

13 Nov '24

Annual Meeting Notice

12 Nov '24

FDA Acceptance Announcement

21 Oct '24

Patient Treatment Update

10 Oct '24

FDA Approval Announcement

20 Sep '24

Investor Conference Partici...

22 Aug '24

Financial Results Update

14 Aug '24

Interim Financial Report

14 Aug '24

Press Release Update

25 Jun '24

Conference Announcement

21 May '24

Financial Results Update

20 May '24

Treatment Announcement

13 May '24

Preclinical Data Release

6 May '24

Investor Conference Notice

1 May '24

Event Announcement

25 Mar '24

Financial Results Update

7 Mar '24

Conference Participation

26 Feb '24

External Links:

SEC

On January 5, 2026, Alpha Tau Medical Ltd. announced it submitted its first Pre-Market Approval Module to the FDA for Alpha DaRT® to treat Recurrent Cutaneous Squamous Cell Carcinoma (cSCC). This filing is significant for the company as it marks a crucial step in their product approval process.

AI Assistant

ALPHA TAU MEDICAL LTD

2026

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.